Latest Trials Flashcards
1
Q
What did the recently published (2024) Phase 3 INVIGORATE-2 study demonstrate?
A
IV secukinumab led to significant and sustained improvements in clinical measures of PsA, and the safety profile was similar to that of subcut secukinumab.
